Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca Inks a Deal for Production of at Least 100 Million Doses of Coronavirus Vaccine for the Chinese Market

By Eric Volkman – Aug 7, 2020 at 6:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company has granted its partner exclusive rights to AZD1222 in China.

AstraZeneca (AZN 0.06%) has filled a notable gap in its coronavirus vaccine production plans. On Thursday, the sprawling pharmaceutical company announced in a social media post that it had made a deal to have BioKangtai Biologics produce a minimum of 100 million doses of its AZD1222 vaccine candidate in China for that country's immense market.

Guangdong-based BioKangtai has been granted exclusive rights to develop, produce, and market the vaccine in China. AstraZeneca did not disclose the financial terms of the arrangement, but it did say the collaboration might not remain limited by that country's borders. "In the future, the two parties will continue to explore the possibility of cooperation in other regions and markets," it wrote.

A young girl in a face mask receiving a shot from a medical professional.

Image source: Getty Images.

AZD1222 is one of the leading coronavirus vaccine candidates; a phase 1/2 clinical trial of it showed that, after one month, it produced the type of neutralizing antibodies that can keep the coronavirus at bay in nearly all of the 35 participants inoculated.

AstraZeneca is developing AZD1222 in collaboration with the U.K.'s University of Oxford. The company has now covered most global markets with production deals, but those, of course, will kick in only if the  candidate performs well enough in late-stage clinical testing and is subsequently approved by regulators. AstraZeneca and Oxford began a 2/3 phase clinical trial of it in May.

Anticipating that levels of demand for an effective COVID-19 vaccine are likely to be unprecedented, the company has ambitions to produce 2 billion doses of AZD1222 by the end of next year. It has already pledged to supply 300 million doses to the U.S. market and 300 million to the countries of the European Union, among other promises.

Shares of AstraZeneca fell 1.4% on Friday, in contrast to the S&P 500 index, which closed with a gain of less than 0.1%.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.21 (0.06%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.